PMID: 16041May 1, 1977

Comparison of triazolam, flurazepam, and placebo as hypnotics in geriatric patients with insomnia

Journal of Clinical Pharmacology
R L Reeves

Abstract

The safety and efficacy of 0.25 mg triazolam were compared to those of 15 mg flurazepam and placebo in 41 geriatric outpatients suffering from insomnia. The patients were randomly assigned to one of the three treatment groups. The medication was taken at bedtime for 28 days. Tolerance development was also studied. Triazolam was found to be significantly better than placebo in how much the medication helped the patients sleep, in sleep onset, in duration of sleep, number of nighttime awakenings, in quality (depth) of sleep, and in feeling of restfulness in the morning. Triazolam was significantly better than flurazepam in duration of sleep and was rated higher than flurazepam in all other variables. Flurazepam was significantly better than placebo in only two variables--onset of sleep and quality (depth) of sleep. Side effects were reported in each treatment group, and one patient on placebo discontinued because of side effects. There was no decrease in hypnotic effect over this four-week period, therefore, no evidence of tolerance development on either of the active compounds. Both active compounds provided the same amount of relief from insomnia after four weeks as they had after one week. Laboratory analyses and poststudy phy...Continue Reading

References

Jan 1, 1975·Psychopharmacologia·G VogelK Sexton
Sep 11, 1975·Clinical Pharmacology and Therapeutics·K RickelsA Schilling
Feb 1, 1974·Journal of Clinical Pharmacology·W VeldkampH V Demissianos

Citations

Aug 19, 1989·Lancet·I Oswald
Jun 19, 2001·Experimental Gerontology·V N Anisimov
Dec 1, 1988·American Journal of Public Health·P A RobersB L Svarstad
Nov 15, 2005·BMJ : British Medical Journal·Jennifer GlassUsoa E Busto
Jan 1, 1983·British Journal of Clinical Pharmacology·H BeckJ Holzer
May 1, 1983·Journal of Clinical Pharmacology·K RickelsR Weinstock
Mar 4, 2008·Respiratory Medicine·Gerben StegeYvonne F Heijdra
Sep 10, 2019·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Andrew D KrystalLiza H Ashbrook
Jan 1, 1982·Journal of the American Geriatrics Society·W C DementM A Carskadon
May 1, 1983·Pharmacotherapy·T RothF Zorick
Jul 1, 1983·Drug Intelligence & Clinical Pharmacy·P D Kroboth, R P Juhl
Jan 1, 1980·The Journal of International Medical Research·V PegramP Linton
Jan 1, 1981·British Journal of Clinical Pharmacology·R P Purpura
Jan 1, 1978·The Journal of International Medical Research·A J Bowen
Jan 1, 1978·The Journal of International Medical Research·K K Okawa, G S Allens
Sep 7, 2018·Harvard Review of Psychiatry·Lauren B GerlachDonovan T Maust
Jan 25, 2002·European Journal of Cancer Care·S Ancoli-IsraelV Jones

Related Concepts

Clinical Trials
Drug Tolerance
Staurodorm
Sedatives
Transient Insomnia
Placebos
Sleep, Slow-Wave
Anti-Anxiety Effect
Trilam

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Pediculosis pubis

Pediculosis pubis is a disease caused by a parasitic insect known as Pthirus pubis, which infests human pubic hair, as well as other areas with hair including eye lashes. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Rh Isoimmunization

Rh isoimmunization is a potentially preventable condition that occasionally is associated with significant perinatal morbidity or mortality. Discover the latest research on Rh Isoimmunization here.

Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

Enzyme Evolution

This feed focuses on molecular models of enzyme evolution and new approaches (such as adaptive laboratory evolution) to metabolic engineering of microorganisms. Here is the latest research.

Alignment-free Sequence Analysis Tools

Alignment-free sequence analyses have been applied to problems ranging from whole-genome phylogeny to the classification of protein families, identification of horizontally transferred genes, and detection of recombined sequences. Here is the latest research.